Low ETV1 mRNA expression is associated with recurrence in gastrointestinal stromal tumors

Keiichi Sakamaki1, Kohei Funasaka2,3, Ryoji Miyahara1

  • 1Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.

Scientific Reports
|September 9, 2020
PubMed

Insights

Low expression of ETS translocation variant 1 (ETV1) in gastrointestinal stromal tumors (GISTs) indicates a higher risk of recurrence. High ETV1 expression is linked to longer recurrence-free survival, suggesting ETV1 as a potential marker for GIST aggressiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Gastrointestinal stromal tumors (GISTs) often have KIT mutations, but clinical outcomes vary.
  • The ETS translocation variant 1 (ETV1) gene's role in GIST clinical behavior is not well understood.

Purpose of the Study:

  • To investigate ETV1 gene expression in GISTs.
  • To determine the association between ETV1 expression levels and GIST clinical features, including recurrence risk.

Main Methods:

  • A cohort study of 64 patients who underwent GIST surgical resection.
  • Quantitative analysis of ETV1 mRNA expression in GIST samples compared to non-GIST tissues.
  • Statistical analysis to correlate ETV1 expression with recurrence and recurrence-free survival (RFS).

Main Results:

  • GIST samples showed significantly higher ETV1 mRNA expression than non-GIST samples (P < 0.0001).
  • Low ETV1 expression was identified as an independent predictor of recurrence (HR: 8.1), alongside tumor size and mitotic index.
  • Patients with high ETV1 expression had significantly longer RFS than those with low ETV1 expression (P = 0.025).

Conclusions:

  • Low ETV1 expression is an independent prognostic factor for recurrence in GIST patients post-surgery.
  • ETV1 expression levels may serve as a biomarker for predicting the aggressiveness of malignant GISTs.